DUBLIN--(BUSINESS WIRE)--The "Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The market of Thrombocytopenia in 7MM was found to be USD 1,248 million in 2016.
Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Thrombocytopenia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Key Topics Covered:
1. Key Insights
2. Thrombocytopenia Market Overview at a Glance
2.1. Market Share (%) Distribution of Thrombocytopenia in 2017
2.2. Market Share (%) Distribution of Thrombocytopenia in 2027
3. Disease Background and Overview: Thrombocytopenia
3.1. Introduction
3.2. Causes of Thrombocytopenia
3.3. Pathogenesis
3.4. Pathophysiology
3.5. Etiology
3.6. Symptoms
3.7. Diagnosis and Treatment
3.8. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
3.9. Management of thrombocytopenia
3.10. First Line Therapies
3.11. Second and Third Line Therapies
3.12. Diagnostic and treatment guidelines form thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
3.13. Treatment of Heparin-induced Thrombocytopenia (HIT)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Thrombocytopenia
4.4. Country Wise-Epidemiology of Thrombocytopenia
5. Unmet needs
6. Marketed Products
7. Octagam: Octapharma USA
7.1. Product Description
7.2. Regulatory Milestones
7.3. Advantages & Disadvantages
7.4. Safety and Efficacy of Octagam
7.5. Side effects of Octagam
7.6. Product Profile
8. Nplate(AMG-531): Amgen
8.1. Product Description
8.2. Regulatory Milestones
8.3. Advantages & Disadvantages
8.4. Safety and Efficacy of Nplate
8.5. Side effects of Nplate
8.6. Product Profile
9. MULPLETA (Lusutrombopag): Shionogi
9.1. Product Description
9.2. Regulatory Milestones
9.3. Safety and Efficacy of Lusutrombopag/MULPLETA
9.4. Side effects of MULPLETA
9.5. Product Profile
10. Privigen: CSL Behring
11. Rhophylac: CSL Behring
12. Emerging Therapies
13. Filed & Phase III Drugs
13.1. Avatrombopag: Dova Pharmaceuticals
13.2. Fostamatinib: Rigel Pharmaceuticals
13.3. Caplacizumab: Ablynx
13.4. BT-595: Biotest
13.5. SHP655: Shire
14. Phase II Drugs
14.1. PRN-1008: Principia Biopharma
14.2. PRTX-100: Protalex
14.3. Rozanolixizumab: UCB Biopharma
14.4. Efgartigimod: Argenx
14.5. Veltuzumab: Immunomedics
15. Thrombocytopenia: Market Analysis
15.1. Key Findings
16. Thrombocytopenia: Total Market Size in 7MM
16.1. Total Market Size of Thrombocytopenia in 7MM
16.2. Type Specific Market Size of Thrombocytopenia in 7MM
17. Market Size of Thrombocytopenia by Country
18. Market Drivers
19. Market Barriers
20. Appendix
Companies Mentioned
- Octapharma USA
- Amgen
- Shionogi
- CSL Behring
- Dova Pharmaceuticals
- Rigel Pharmaceuticals
- Ablynx
- Biotest
- Shire
- Principia Biopharma
- Protalex
- UCB Biopharma
- Argenx
- Immunomedics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gl9vmc/thrombocytopenia?w=4
